x

Posted 12 March, 2024

Imunon, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:IMNN in a 8-K filed on 12 March, 2024.


  On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the "Board") of Imunon, Inc. (the "Company") of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Imunon, Inc.
Health Care/Life Sciences • Biotechnology
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Market Cap
$13.4M
View Company Details
Imunon, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the "Board") of Imunon, Inc. (the "Company") of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024. Dr. Le Goff's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.


The Company is conducting a search for Dr. Le Goff's successor as Chief Executive Officer. Michael H. Tardugno, the Company's Executive Chairman, and Chief Executive Officer prior to Dr. Le Goff, will assume day-to-day leadership of the Company until such successor is named and will continue in his role directing Company strategy.